Press Releases

---------------------------------------------------------------- FOR IMMEDIATE RELEASE

CONTACTS:	César García, President and Chief Executive Officer
	818-709-1244 x 7123
	Robert Mello, President
	IRIS Sample Processing, 781-551-0100 x 6126
	Or
	Ron Stabiner, The Wall Street Group, Inc.
	212-888-4848

IRIS INTERNATIONAL'S SAMPLE PROCESSING DIVISION SIGNS FIVE-YEAR EXCLUSIVE SUPPLY AGREEMENT WITH IDEXX LABORATORIES

Covers StatSpin^® VT Multipurpose Veterinary Centrifuge

CHATSWORTH, Calif., June 27, 2006 — IRIS International, Inc. (NASDAQ: IRIS) a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and clinical reference laboratories worldwide, today announced that its Sample Processing Business Unit has signed a five-year exclusive supply agreement for its flagship veterinary centrifuge with IDEXX Laboratories, Inc. (NASDAQ: IDXX) of Westbrook, ME.

Under the terms of the agreement, IRIS will be the sole supplier of the Statspin^® VT and similar stand alone veterinary centrifuges for all of IDEXX's in-clinic needs in the U.S. and Europe. Projected sales, service and spare parts revenue over the life of the contract is estimated at around $11 million.

"We are extremely pleased to extend our long-term relationship with IDEXX Laboratories," stated Robert Mello, IRIS Corporate Vice President and President of the Sample Processing Business Unit. "Our association with IDEXX goes back to the late 1980s when we introduced our first StatSpin multipurpose centrifuge for clinical and animal health diagnostics. The close relationship between our two companies is reinforced by the fact that under the agreement the VT centrifuge will carry both the StatSpin and IDEXX brand names."

"The Sample Processing Business Unit continues to develop innovative new devices that make a strong contribution to the Company's growing product portfolio," stated IRIS President and Chief Executive Officer César García. "We are pleased that IDEXX, a leader in animal health serving practicing veterinarians worldwide, recognizes the value of our products."

"Our continuing relationship with IRIS International reflects our desire to provide veterinarians the best possible medical and clinical instrumentation available for ensuring the well-being of animals," stated Michael Williams Vice President and General Manager of IDEXX VetLab Instrumentation. "IDEXX looks forward to sharing the respected StatSpin name on a high-quality centrifugal product for meeting the sample processing needs of the veterinarians we serve."

About IDEXX Laboratories

IDEXX Laboratories, Inc. (www.idexx.com), is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. IDEXX's products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,000 people and offers products to customers in over 100 countries.

The Company

IRIS International, Inc. (http://www.proiris.com), based in Chatsworth, Calif., is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit (formerly the StatSpin^® subsidiary) (www.statspin.com), based in Westwood, Mass., manufactures innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR) (www.adires.com), based near Houston, Texas, is the Company's imaging research and development subsidiary. The IRIS Molecular Diagnostics (IMD) Subsidiary develops innovative ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets.

SAFE HARBOR PROVISION

This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, new product introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of international sales; reliance on key suppliers; the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures; potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and competitive factors, including pricing pressures and the introduction by others of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.